Background: Infection with Hepatitis C virus (HCV) is a major cause of chronic liver disease, WHO estimated that about 170 million people are infected with Hepatitic C virus, Silymarin (Legalon) have been recently shown to be effective in treatment of Hepatitic C virus infection. Objectives: The effectiveness of Legalon (Silymarin) on viral load in patients with Hepatitic C virus infection.
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Introduction:
Infection with hepatitis C virus (HCV), is a major cause of chronic liver disease, WHO estimated that about 170 millions people (3% of the world's population) are infected with HCV and 3 -4 millions persons are newly infected each year.
(1-3) Prevalence rates vary widely, ranging from 0.15% in Scandinavia to about 15% in Egypt. (4). the overall prevalence in United States is 1.8%, corresponding to an estimated 3.9 million persons with HCV infection. (5). about 80% of newly infected patients progress to develop chronic infection and Cirrhosis develops in about 10-20% of persons with chronic infection. Liver cancer develops in 1-5% of persons with chronic infection over a period of 20 -30 years. (5,6) . Diagnostic tests for hepatitis C virus (HCV) can be either: 1-Serologic assays that detect antibodies to Hepatitis C. 2-Molecular assays that detect or quantify HCV RNA. (7, 8, 9 ,) Treatment of HCV RNA or Viral Load, Viral load is an important determinant of treatment response. The lower the HCV RNA (viral load) the better the chance of eradicating the hepatitis C virus. Low viral load under: 800 000 IU/mL, High viral load: over800 000 IU/mL. some recent studies have suggested that the cut-off between low and high viral load may be too high. These studies have shown that people with viral load under 400 000 -600 000 IU/mL respond better to current medications compared to those who have a viral load above 400 000 -600 000 IU/mL. (10) The goal of antiviral therapy in patients with chronic HCV is to eradicate HCV RNA, which is predicted by attainment of a sustained virologic response (SVR). An SVR is associated with a 98 to 100 % chance of being HCV RNA negative during long term follow -up (11,12) . And attaining an SVR has been associated with decreases in all-cause mortality, liver related death, need for liver transplantation, hepatocellular carcinoma rates, and liver related complications (12, 13) . Patients with genotype 1 should be treated with Peginterferon, ribavirin, and a protease inhibitor. Patients with other genotypes are treated with Peginterferon and ribavirin; all have new modalities for interferon free drugs.14 Peginterferon alfa-2a and Peginterferon alfa-2b differ in their pharmacokinetics. Studies comparing the two Peginterferons in combination with ribavirin have had variable results (10, 13, 15) . While the largest randomized trail (IDEAL) showed that Peginterferon alfa-2a and Peginterferon alfa -2b appeared to have comparable efficacies in the treatment of chronic hepatitis C (16). in 2010 meta-analysis suggests a slight advantage for Peginterferon alfa-2a (17). For patients receiving Peginterferon alfa-2a, the ribavirin dose is 1000 mg for patients who weight <= 75 kg or 1200 mg for those weight > 75 kg. For patents receiving Peginterferon alfa2b, the ribavirin dose is 800 mg for patients who weight < 65 kg or 1000 mg for those weights 65-85 kg, 1200 mg for > 85 to 105 kg, 1400 mg for > 105 kg. 18 Side effects are observed
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in almost 80% of patents receiving Peginterferon and ribavirin combination therapy for chronic HCV. (19, 20) include: Flu-like symptoms, anemia, neutropenia, thrombocytopenia, rashes, hair loss, thyroid dysfunction, depression, fatigue, irritability and mania, non-productive cough, dyspnea, ophthalmologic disorders such as retinal hemorrhage, teratogenicity, and exacerbations of autoimmune diseases. 21, 22 Legaon-SIL (LS) is a form of SBN (silybummarianum) which is water -soluble formulation of the dihydro-succinate sodium salt of SBN A and SBN B in equal proportion. Recent results from a pilot study in patients with chronic HVC using LS indicate that some Flavonolignans may have antiviral activity (24, 25) Silibinin is assumed to be partly reabsorbed after being deconjugated again and enters into an entero-hepatic circulation. Legalon given for three months duration with pegylated interferon and ribavirin (23,24) Milk thistle seed work might protect liver cells from toxic chemicals and drugs. It also seems to have antioxidant and anti-inflammatory effects. Milk thistle plant extract might enhance the effect of estrogen and some research suggests that milk thistle may limit liver damage after exposure to industrial poisons such as toluene and xylene.
Aim of the Study:
To study the effects of Legalon treatment in addition to Peginterferon & ribavirin on viral load in hepatitis C virus as compared to those receiving only Peginterferon & ribavirin at the end of 12 weeks treatment in the medical city of Baghdad teaching hospital.
Patients and Methods
In a prospective case control study all 400 patients with hepatitis c virus infections fulfilled the criteria of treatment, patients were randomized given either peg.interferon, ribavirin and legalon (silymarin) or peg.interferon and ribavirin. 200 patients were given a triple therapy for 12 weeks group (A). Age, sex and weight of the patients were recorded. The other 200 patients received peg.interferon and ribavirin group (B) with age, sex and weight of the patients were recorded The study was conducted in the Medical City Baghdad teaching Hospital, from July 2012 to November 2013. Quantitative Viral load assessed initially and then after 12 weeks for all studied group with testing liver biochemistry and complete blood picture . Viral load considered high if it's > 600,000 iu/ml and viral load consider low when it's < 600,000 iu /ml [34] . Patients only with Gl & G 4 included in this study. We excluded the pregnancy, decompensated liver failure, HBV, renal failure, we considered time patient response' when. >= 2 log decrease or undetectable at end of 12 weeks from initial viral load (partial or early virological response). Statistical analysis: The statistical analysis and data management were performed by using the statistical package for social sciences (SPSS) version 20, IBM, US, 2010. Descriptive statistics were presented as mean and standard deviation (SD) for the mean age, and frequencies and proportions for other variables. The response rate was calculated as the number of cases with viral load < 2 log or undetected levels divided by the total number of cases in the group. Student's t test was used to compare the mean age of cases in between the two studied group. Chi square test (X2) was used to compare between the studied groups regarding the categorical variables, including the sex, the change in hematological parameters and the total response according to the genotypes
Results
There were 400 cases enrolled in this study, represent the two studied groups, group A treated with Pegylated interferon and Ribavirin with Legalon and group B (without Legalon), each group consisted of 200 cases. Age Distribution: Was in group A (41.3± 10.3) years with a range of 19 -73 years, and it was (42.5 ± 9.1) years with a range of 21 -63 years in group B, the difference in age was statistically insignificant, P>0.05, table 1. Sex distribution: In group A males and females were about equally distributed, 98 males (49%) and 102 (51%) females, with a female to male ratio of 1.04:1. In group B, males were 110 (55%) and females were 90 (45%) with a female to male ratio of 1.22:1.
The mean weight of the patients in group A was 77.8 ± 14.4 kg\m2 and 76.3 ±13.6 kg\m2 in group B with no statistically significant difference in between both groups (P=0.45). Comparison study between the treatment of Hepatitis C virus with (peg-interferon, Khalid A. Al-Khazraji ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. In group B it had been also found that cases with genotype 1 and viral load of < 600000 had significantly (P=0.022) higher response rate than those with viral load > 600000 of the same genotype group, (Table 2) . On the other hand in those cases with genotype 4 ,the response rate was higher in those with viral load <600 than those with viral load >600000 and the differences was statistically significant (p=0.003), Table 2 . Furthermore the overall response rate of cases with viral load < 600 was higher than those with viral load > 600000. Comparison study between the treatment of Hepatitis C virus with (peg-interferon, Khalid A. Al-Khazraji ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital.
The comparison of response rate of the cases with genotype 1 vs. those in group B with the same genotype, revealed that cases with genotype 1 in group A had higher response rate than those in group B, 78.9% vs. 54.5% respectively, (P = 0.006), Table 6 . Comparison of response to treatment of cases with genotypes 4 of group A vs. group B Table 7 shows the response rate of cases with genotype 4 in both studied group, the response rate was 69.8% genotype 4 cases of group A which was higher than the 55.6% of cases in group B with genotype 4, however the difference in response rate didn't reach the statistical significance (P>0.05). in our results were not agreed with our findings.The difference might be because of that they don't use ribavirin ,peg. interferon and Genotypes of patients. Treatment with Legalon (silymarin) down regulates HCV Gl, which means decrease HCVRNA titer after treatment with silymarin this study which support our study Hamid Kalantaria et al indicated that in 55 patients with chronic hepatitis C performing silymarin (650 mg/day) for 6 months, improving serum HCV-RNA titer, serum aminotransferases (ALT, AST), hepatic fibrosis and patient's quality of life. This study support our study for the effectiveness on the viral load. Peterferenci. et al find in 16 patients received 10 mg/kg/day silymarin (LegalonSil; Madaus, Koln, Germany) for 7 days. In a subsequent dose-finding study, 20 patients received 5, 10, 15, or20 mg/kg/day SIL for 14 days. In both protocols, PegIFN-2a/RBV were started on day 8. Viral load was determined daily, HCV-RNA, at week 12, was significantly decreased. This study support our result by decreased HCV viral load titer by silymarin. Other studies done In Shepherd, J. et al this study supported our result of the lowest response in Gl (without legalon) as compared to G4 (without legalon),there was more response in genotype 4 but, statistically insignificant regarding the group B. In Wirth S. et al [70 two studies stratified the results in genotype 1 patients according to the viral load before treatment. In the first study, the cut-off level was 600.000 U/L: 32% of patients with genotype 1 and high viral load (>600:000 U/L) and 73% with low viral load (<600,000 U/L) achieved SVR. The differences in response according to viral load in both group (A) response to treatment was more in viral load <600000 IU/ml as compared with viral load>600000 IU/ml. Response was statistically significant in group (A) and more with (viral load<600000iu/ml) and less in the (viral load >600000iu/ml) ;the differences was statistically significant. Our results were also supported by FuadHasan MD et al[71] This support is for our study regarding G4 viral load as we found an increase in response regarding the low viral load . In our study we found increased response in G 4 HCV in the
